Drug
Tolvaptan
Tolvaptan: highest development phase Phase 3, developed by Otsuka. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Otsuka
Trials
| Drug | Phase | Indication |
|---|---|---|
| Tolvaptan Suspension NCT04782258 | Phase 3 | Autosomal Recessive Polycystic Kidney (ARPKD) |
| Tolvaptan NCT01336972 | Phase 2 | Autosomal Dominant Polycystic Kidney Disease |
Latest
No recent events.
Follow Tolvaptan on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.